Speaker: John Schiel, Nist, USA

The Antibodies in Solution: a LINXS – NIST Webinar Series provides background information related to the currently ongoing LINXS antibody research program. This is a concerted experimental and theoretical effort that aims to investigate the properties of monoclonal antibodies in solution, which comprise a major platform for potential drug candidates and are of high academic and pharmaceutical interest. An international consortium of researchers at academic institutions, research centers, NIST and Novartis has teamed up for this. Didactical lectures given by members of the consortium on different experimental and theoretical topics that are highly relevant for state-of-the-art antibody research as well as insights from pharmaceutical industry will be broadcasted. A central aspect of the webinar series will be to illustrate the full power of neutron and X-ray scattering science that can be achieved in combination with complementary experimental methods and different unifying simulation techniques.

Bio:

Dr. Schiel received his BS (2004) and Ph.D. (2009) in chemistry from the University of Nebraska-Lincoln, and is currently serving as the Federal Technical Program Manager for NIIMBL, a Manufacturing USA institute accelerating adoption of advanced biomanufacturing technologies. Dr. Schiel also maintains a research lab in the NIST Biomolecular Measurement Division. Dr. Schiel coordinates the development of Reference Materials that support the biomanufacturing industry, including the recombinant IgG1κ NIST monoclonal antibody Reference Material 8671 (NISTmAb).  He also leads an analytical research team developing innovative approaches toward production/characterization of next generation biotherapeutics (e.g. viral vectors, cell therapy products, and vaccines) and de-risking of innovative technologies for lifecycle appropriate implementation and regulatory assimilation.  Dr. Schiel joined the Office of Advanced Manufacturing as a Federal Technical Program Manager for NIIMBL in 2021. In this role he inspires an innovative and interconnected advanced biopharmaceutical manufacturing ecosystem by working across academic, industry, and federal stakeholders.  He is an author of over 30 publications, an editor of the ACS book series “State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization”, and recipient of numerous Awards including the Arthur S. Flemming Award, Department of Commerce Gold Medal, ACS Division of Analytical Chemistry Fellowship, Bioanalysis Young Investigator Award, and UNL Early Achiever Award.  

Abstract:
NISTmAb and More: Standards and Technology Paved by the Community

The NIST Initiative in Biomanufacturing seeks to promote advances in measurement science, standards and technologies that can accelerate the development of medicines that improve patient health.  The NISTmAb represents one of many successes of the program whereby the global biomanufacturing community convened to innovate.  The NIST team (along with hundreds of collaborators) established the NISTmAb Reference Material 8671, an industry-wide test metric to evaluate performance of emerging technologies, foster collaboration, and spur innovation in the biomanufacturing industry. This presentation will provide an overview of the NISTmAb, the series of community-driven projects enabled by this material, and a perspective on how common vision and collaboration can advance the next generation of quality healthcare solutions.